#China #Shanghai #Antengene #ATG-207 #TGF-β

Antengene's Breakthrough Presentation at EULAR 2026

Antengene Corporation Limited, a prominent global biotechnology firm based out of Shanghai and Hong Kong, is poised to make significant waves at the upcoming 2026 European Congress of Rheumatology (EULAR 2026), scheduled from June 3 to 6 in London. The company will present vital preclinical data regarding its innovative therapeutic candidate, ATG-207, which is a bifunctional fusion protein targeting αCD3 and TGF-β.

The Significance of ATG-207

ATG-207 is engineered to tackle the challenges posed by T cell-mediated autoimmune diseases, where there is often an unmanageable overactivation of pathogenic T cells. This therapy aims to not only modulate these T cells but also promote the induction of regulatory T cells, offering a novel dual mechanism of action that could fundamentally alter treatment paradigms in this difficult-to-treat area.

The lack of sufficient treatments for controlling pathogenic T cells and restoring immune balance underscores the need for effective therapies that can provide long-term immune tolerance. Antengene's ATG-207 is designed to fill this gap by selectively suppressing harmful T cells while enhancing regulatory T cell activity, which is crucial for maintaining immune homeostasis.

Preclinical Validation: An Inside Look

The abstract for the poster presentation at EULAR 2026 presents key findings from preclinical studies of ATG-207. These studies evaluated multiple parameters such as receptor binding, T cell modulation, cytokine release profiles, and therapeutic efficacy in animal models of T cell-mediated autoimmune disease. The results revealed that ATG-207 effectively binds preferentially to the TGFβRIII receptor and successfully downregulates surface T cell receptor expression.

Moreover, the therapy demonstrated a pronounced ability to induce regulatory T cells in laboratory settings, hinting at its potential in achieving a stable immune balance. Notably, compared to control proteins, ATG-207 resulted in significantly reduced levels of pro-inflammatory cytokines in both human blood samples and in mouse studies, showcasing its capability to mitigate inflammation effectively.

Essential Presentation Details

• - Poster Title: A masked and TGFβRIII-biased αCD3-TGF-β fusion protein promotes regulatory T cell induction and immune tolerance
• - Poster Number: POS-1110
• - Session: Poster View VIII
• - Date: June 6, 2026
• - Time: 10:15 British Summer Time / 17:15 Beijing Time

About Antengene

Antengene Corporation focuses on developing cutting-edge therapeutics that target various ailments, particularly those with substantial unmet medical needs such as autoimmune diseases and cancers. With a robust pipeline that includes several investigational candidates, the company aims to lead advancements in these critical areas of healthcare. Their proprietary AnTenGager® platform plays a pivotal role in refining T cell engagement strategies, allowing potential new treatments to navigate the complexities of the immune response efficiently.

As of now, Antengene has achieved significant regulatory milestones, including 32 investigational new drug approvals across the U.S. and Asia and numerous new drug application approvals across Asia-Pacific markets. The organization's lead product, XPOVIO® (selinexor), is already approved in multiple jurisdictions, demonstrating the firm’s commitment to enhancing patient outcomes through innovation.

Conclusion

The presentation at EULAR 2026 marks a key milestone for Antengene as it unveils its innovative approaches to addressing autoimmune diseases. The preclinical data on ATG-207 signals promise not only for the company's pipeline but also for patients in need of more effective treatments—ushering in a potential new era in the management of autoimmune conditions. Antengene's advancements emphasize both its dedication to scientific innovation and the urgent necessity of finding viable therapeutic options for challenging health crises.